113 related articles for article (PubMed ID: 2803908)
1. Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma.
Kerr DJ; Maughan T; Newlands E; Rustin G; Bleehen NM; Lewis C; Kaye SB
Br J Cancer; 1989 Jul; 60(1):104-6. PubMed ID: 2803908
[TBL] [Abstract][Full Text] [Related]
2. Phase II trials with flavone acetic acid (NCS. 347512, LM975) in patients with advanced carcinoma of the breast, colon, head and neck and melanoma.
Kaye SB; Clavel M; Dodion P; Monfardini S; ten Bokkel-Huinink W; Wagener DT; Gundersen S; Stoter G; Smith J; Renard J
Invest New Drugs; 1990; 8 Suppl 1():S95-9. PubMed ID: 2380021
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of flavone acetic acid (NSC 347512, LM975) in patients with pediatric malignant solid tumors.
Pratt CB; Relling MV; Meyer WH; Douglass EC; Kellie SJ; Avery L
Am J Clin Oncol; 1991 Dec; 14(6):483-6. PubMed ID: 1957836
[TBL] [Abstract][Full Text] [Related]
4. A phase I clinical trial of flavone-8-acetic acid in combination with interleukin 2.
Holmund JT; Kopp WC; Wiltrout RH; Longo DL; Urba WJ; Janik JE; Sznol M; Conlon KC; Fenton RG; Hornung R
J Natl Cancer Inst; 1995 Jan; 87(2):134-6. PubMed ID: 7707385
[No Abstract] [Full Text] [Related]
5. Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: a phase II study.
Thatcher N; Dazzi H; Mellor M; Ghosh A; Carrington B; Johnson RJ; Loriaux EM; Craig RP
Br J Cancer; 1990 Apr; 61(4):618-21. PubMed ID: 2331447
[TBL] [Abstract][Full Text] [Related]
6. Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma: I. Clinical and vascular studies.
O'Reilly SM; Rustin GJ; Farmer K; Burke M; Hill S; Denekamp J
Br J Cancer; 1993 Jun; 67(6):1342-5. PubMed ID: 8512818
[TBL] [Abstract][Full Text] [Related]
7. Clinical and pharmacokinetic phase I trial with the diethylaminoester of flavone acetic acid (LM985, NSC 293015).
Dodion PF; Abrams J; Gérard B; Crespeigne N; Peeters B; Van Berchem C; Kenis Y
Eur J Cancer Clin Oncol; 1987 Jun; 23(6):837-42. PubMed ID: 3653200
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial with Flavone Acetic Acid (NSC.347512, LM975) in patients with non-small cell lung cancer.
Siegenthaler P; Kaye SB; Monfardini S; Renard J
Ann Oncol; 1992 Feb; 3(2):169-70. PubMed ID: 1318743
[No Abstract] [Full Text] [Related]
9. Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma. IV: Pharmacokinetics and toxicity of flavone acetic acid and its metabolites.
Stratford MR; Rustin GJ; Dennis MF; Watfa RR; Howells N; O'Reilly SM
Br J Cancer; 1993 Jun; 67(6):1351-5. PubMed ID: 8512820
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of flavone acetic acid.
Kerr DJ; Kaye SB; Cassidy J; Bradley C; Rankin EM; Adams L; Setanoians A; Young T; Forrest G; Soukop M
Cancer Res; 1987 Dec; 47(24 Pt 1):6776-81. PubMed ID: 3677106
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic study of LM985 (flavone acetic acid ester).
Kerr DJ; Kaye SB; Graham J; Cassidy J; Harding M; Setanoians A; McGrath JC; Vezin WR; Cunningham D; Forrest G
Cancer Res; 1986 Jun; 46(6):3142-6. PubMed ID: 3698028
[TBL] [Abstract][Full Text] [Related]
12. Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma. III: Cytokine studies.
Haworth C; O'Reilly SM; Chu E; Rustin GJ; Feldmann M
Br J Cancer; 1993 Jun; 67(6):1346-50. PubMed ID: 8512819
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacology study of flavone acetic acid administered two or three times weekly without alkalinization.
de Forni M; Chabot GG; Armand JP; Gouyette A; Klink-Alak M; Recondo G
Cancer Chemother Pharmacol; 1995; 35(3):219-24. PubMed ID: 7805180
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma.
Burdette-Radoux S; Tozer RG; Lohmann RC; Quirt I; Ernst DS; Walsh W; Wainman N; Colevas AD; Eisenhauer EA
Invest New Drugs; 2004 Aug; 22(3):315-22. PubMed ID: 15122079
[TBL] [Abstract][Full Text] [Related]
15. Phase I and clinical pharmacology study of intravenous flavone acetic acid (NSC 347512).
Weiss RB; Greene RF; Knight RD; Collins JM; Pelosi JJ; Sulkes A; Curt GA
Cancer Res; 1988 Oct; 48(20):5878-82. PubMed ID: 3167843
[TBL] [Abstract][Full Text] [Related]
16. Flavone acetic acid (LM 975, NSC 347512). A novel antitumor agent.
O'Dwyer PJ; Shoemaker D; Zaharko DS; Grieshaber C; Plowman J; Corbett T; Valeriote F; King SA; Cradock J; Hoth DF
Cancer Chemother Pharmacol; 1987; 19(1):6-10. PubMed ID: 3545524
[TBL] [Abstract][Full Text] [Related]
17. Tumour concentrations of flavone acetic acid (FAA) in human melanoma: comparison with mouse data.
Maughan TS; Ward R; Dennis I; Honess DJ; Workman P; Bleehen NM
Br J Cancer; 1992 Sep; 66(3):579-82. PubMed ID: 1520597
[TBL] [Abstract][Full Text] [Related]
18. Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG).
Pavlidis N; Aamdal S; Awada A; Calvert H; Fumoleau P; Sorio R; Punt C; Verweij J; van Oosterom A; Morant R; Wanders J; Hanauske AR
Cancer Chemother Pharmacol; 2000; 46(2):167-71. PubMed ID: 10972487
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical and pharmacokinetic trial of flavone acetic acid.
Havlin KA; Kuhn JG; Craig JB; Boldt DH; Weiss GR; Koeller J; Harman G; Schwartz R; Clark GN; Von Hoff DD
J Natl Cancer Inst; 1991 Jan; 83(2):124-8. PubMed ID: 1703237
[TBL] [Abstract][Full Text] [Related]
20. Response to flavone acetic acid (NSC 347512) of primary and metastatic human colorectal carcinoma xenografts.
Giavazzi R; Garofalo A; Damia G; Garattini S; D'Incalci M
Br J Cancer; 1988 Mar; 57(3):277-80. PubMed ID: 3355765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
